FDA Grants Noribogaine IND and ARPA-H Awards Validate Silo Pharma’s PTSD Program
U.S. agencies under the EVIDENT program awarded grants to leading institutions on psychedelic science, reinforcing Silo Pharma’s focus on data-driven PTSD treatments such as its SPC-15 program. The FDA granted IND clearance to a noribogaine candidate for alcohol use disorder and will publish final psychedelic development guidance imminently.
1. Federal Actions Support Psychedelic Research
The Advanced Research Projects Agency for Health under its EVIDENT program announced initial awardees, including Johns Hopkins University and other innovators, to accelerate psychedelic science. In parallel, the FDA issued three National Priority Vouchers to Compass Pathways, Usona Institute and Transcend Therapeutics, signaling regulatory focus on high-impact mental health therapies.
2. FDA Clears Noribogaine IND
The U.S. Food and Drug Administration granted investigational new drug clearance to DemeRx NB’s noribogaine candidate targeting alcohol use disorder. This clearance underscores growing clinical momentum in the psychedelic and psychiatric treatment space, broadening the pathway for novel compounds.
3. Implications for Silo Pharma’s PTSD Program
Silo Pharma highlights that federal funding and regulatory prioritization validate its SPC-15 PTSD program and strategic emphasis on data-driven approaches to neurological and psychiatric disorders. The coordinated federal push is expected to enhance trial recruitment, streamline review timelines and attract partnership opportunities.
4. Imminent Regulatory Guidance for Psychedelic Drugs
Final FDA guidance on psychedelic drug development is set to be published imminently, providing critical clarity on clinical design, safety requirements and regulatory pathways. This milestone is expected to reduce uncertainty for sponsors and accelerate next-generation therapy approvals.